Systemic Lupus Erythematosus – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Systemic Lupus Erythematosus – Pipeline Review, H2 2016’, provides an overview of the Systemic Lupus Erythematosus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus

The report reviews pipeline therapeutics for Systemic Lupus Erythematosus by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Systemic Lupus Erythematosus therapeutics and enlists all their major and minor projects

The report assesses Systemic Lupus Erythematosus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Ablynx NV

ACEA Biosciences, Inc.

Acetylon Pharmaceuticals, Inc.

Actelion Ltd

AiCuris GmbH and Co KG

Amgen Inc.

Anthera Pharmaceuticals Inc

Argos Therapeutics, Inc.

Asahi Kasei Pharma Corp.

Astellas Pharma Inc.

Aurinia Pharmaceuticals Inc

Azano Pharmaceuticals Inc.

Biogen Inc

Biotest AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corporation

Cellular Biomedicine Group, Inc.

CuraVac, Inc.

Daiichi Sankyo Company, Limited

Deltanoid Pharmaceuticals Inc.

Eisai Co., Ltd.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Genentech Inc

Genosco

Genovax S.r.l.

GlaxoSmithKline Plc

HanAll Biopharma Co., Ltd.

Hanmi Pharmaceuticals, Co. Ltd.

Iltoo Pharma

ImmuNext, Inc.

Immungenetics AG

Immunomedics, Inc.

Immupharma Plc

Invion Limited

Johnson & Johnson

Kadmon Corporation, LLC

Karyopharm Therapeutics, Inc.

Kolltan Pharmaceuticals, Inc.

KPI Therapeutics, Inc.

Lead Discovery Center GmbH

LSK BioPartners, Inc.

MacroGenics, Inc.

MedAnnex Ltd

Medestea Research & Production S.p.A.

MedImmune LLC

Merck KGaA

Millennium Pharmaceuticals Inc

Mitsubishi Tanabe Pharma Corporation

Mount Tam Biotechnologies Inc

Neovacs SA

Nippon Chemiphar Co., Ltd.

Nuevolution AB

Omeros Corporation

Parvus Therapeutics, Inc.

Pfizer Inc.

Principia Biopharma Inc.

Ra Pharmaceuticals, Inc.

RedHill Biopharma Ltd.

Redx Pharma Plc

Resolve Therapeutics, LLC

Sanofi

Sarepta Therapeutics, Inc.

SBI Biotech Co., Ltd.

Seattle Genetics, Inc.

Shire Plc

Stemline Therapeutics, Inc.

Takeda Pharmaceutical Company Limited

TheraMAB LLC

Therapix Biosciences Ltd.

Thunderbolt Pharma Inc

TxCell SA

UCB SA

Xencor, Inc.

XTL Biopharmaceuticals Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Systemic Lupus Erythematosus Overview 8

Therapeutics Development 9

Systemic Lupus Erythematosus - Therapeutics under Development by Companies 11

Systemic Lupus Erythematosus - Therapeutics under Investigation by Universities/Institutes 16

Systemic Lupus Erythematosus - Pipeline Products Glance 17

Systemic Lupus Erythematosus - Products under Development by Companies 20

Systemic Lupus Erythematosus - Products under Investigation by Universities/Institutes 27

Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development 28

Systemic Lupus Erythematosus - Therapeutics Assessment 105

Drug Profiles 121

Systemic Lupus Erythematosus - Dormant Projects 381

Systemic Lupus Erythematosus - Discontinued Products 390

Systemic Lupus Erythematosus - Product Development Milestones 392

Appendix 405

List of Tables

List of Tables

Number of Products under Development for Systemic Lupus Erythematosus, H2 2016 22

Number of Products under Development for Systemic Lupus Erythematosus – Comparative Analysis, H2 2016 23

Number of Products under Development by Companies, H2 2016 24

Number of Products under Development by Companies, H2 2016 (Contd..1) 25

Number of Products under Development by Companies, H2 2016 (Contd..2) 26

Number of Products under Development by Companies, H2 2016 (Contd..3) 27

Number of Products under Development by Companies, H2 2016 (Contd..4) 28

Number of Products under Investigation by Universities/Institutes, H2 2016 29

Comparative Analysis by Late Stage Development, H2 2016 30

Comparative Analysis by Clinical Stage Development, H2 2016 31

Comparative Analysis by Early Stage Development, H2 2016 32

Products under Development by Companies, H2 2016 33

Products under Development by Companies, H2 2016 (Contd..1) 34

Products under Development by Companies, H2 2016 (Contd..2) 35

Products under Development by Companies, H2 2016 (Contd..3) 36

Products under Development by Companies, H2 2016 (Contd..4) 37

Products under Development by Companies, H2 2016 (Contd..5) 38

Products under Development by Companies, H2 2016 (Contd..6) 39

Products under Investigation by Universities/Institutes, H2 2016 40

Systemic Lupus Erythematosus – Pipeline by AbbVie Inc, H2 2016 41

Systemic Lupus Erythematosus – Pipeline by Ablynx NV, H2 2016 42

Systemic Lupus Erythematosus – Pipeline by ACEA Biosciences, Inc., H2 2016 43

Systemic Lupus Erythematosus – Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 44

Systemic Lupus Erythematosus – Pipeline by Actelion Ltd, H2 2016 45

Systemic Lupus Erythematosus – Pipeline by AiCuris GmbH and Co KG, H2 2016 46

Systemic Lupus Erythematosus – Pipeline by Amgen Inc., H2 2016 47

Systemic Lupus Erythematosus – Pipeline by Anthera Pharmaceuticals Inc, H2 2016 48

Systemic Lupus Erythematosus – Pipeline by Argos Therapeutics, Inc., H2 2016 49

Systemic Lupus Erythematosus – Pipeline by Asahi Kasei Pharma Corp., H2 2016 50

Systemic Lupus Erythematosus – Pipeline by Astellas Pharma Inc., H2 2016 51

Systemic Lupus Erythematosus – Pipeline by Aurinia Pharmaceuticals Inc, H2 2016 52

Systemic Lupus Erythematosus – Pipeline by Azano Pharmaceuticals Inc., H2 2016 53

Systemic Lupus Erythematosus – Pipeline by Biogen Inc, H2 2016 54

Systemic Lupus Erythematosus – Pipeline by Biotest AG, H2 2016 55

Systemic Lupus Erythematosus – Pipeline by Boehringer Ingelheim GmbH, H2 2016 56

Systemic Lupus Erythematosus – Pipeline by Bristol-Myers Squibb Company, H2 2016 57

Systemic Lupus Erythematosus – Pipeline by Celgene Corporation, H2 2016 58

Systemic Lupus Erythematosus – Pipeline by Cellular Biomedicine Group, Inc., H2 2016 59

Systemic Lupus Erythematosus – Pipeline by CuraVac, Inc., H2 2016 60

Systemic Lupus Erythematosus – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 61

Systemic Lupus Erythematosus – Pipeline by Deltanoid Pharmaceuticals Inc., H2 2016 62

Systemic Lupus Erythematosus – Pipeline by Eisai Co., Ltd., H2 2016 63

Systemic Lupus Erythematosus – Pipeline by Eli Lilly and Company, H2 2016 64

Systemic Lupus Erythematosus – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 65

Systemic Lupus Erythematosus – Pipeline by Genentech Inc, H2 2016 66

Systemic Lupus Erythematosus – Pipeline by Genosco, H2 2016 67

Systemic Lupus Erythematosus – Pipeline by Genovax S.r.l., H2 2016 68

Systemic Lupus Erythematosus – Pipeline by GlaxoSmithKline Plc, H2 2016 69

Systemic Lupus Erythematosus – Pipeline by HanAll Biopharma Co., Ltd., H2 2016 70

Systemic Lupus Erythematosus – Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 71

Systemic Lupus Erythematosus – Pipeline by Iltoo Pharma, H2 2016 72

Systemic Lupus Erythematosus – Pipeline by ImmuNext, Inc., H2 2016 73

Systemic Lupus Erythematosus – Pipeline by Immungenetics AG, H2 2016 74

Systemic Lupus Erythematosus – Pipeline by Immunomedics, Inc., H2 2016 75

Systemic Lupus Erythematosus – Pipeline by Immupharma Plc, H2 2016 76

Systemic Lupus Erythematosus – Pipeline by Invion Limited, H2 2016 77

Systemic Lupus Erythematosus – Pipeline by Johnson & Johnson, H2 2016 78

Systemic Lupus Erythematosus – Pipeline by Kadmon Corporation, LLC, H2 2016 79

Systemic Lupus Erythematosus – Pipeline by Karyopharm Therapeutics, Inc., H2 2016 80

Systemic Lupus Erythematosus – Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016 81

Systemic Lupus Erythematosus – Pipeline by KPI Therapeutics, Inc., H2 2016 82

Systemic Lupus Erythematosus – Pipeline by Lead Discovery Center GmbH, H2 2016 83

Systemic Lupus Erythematosus – Pipeline by LSK BioPartners, Inc., H2 2016 84

Systemic Lupus Erythematosus – Pipeline by MacroGenics, Inc., H2 2016 85

Systemic Lupus Erythematosus – Pipeline by MedAnnex Ltd, H2 2016 86

Systemic Lupus Erythematosus – Pipeline by Medestea Research & Production S.p.A., H2 2016 87

Systemic Lupus Erythematosus – Pipeline by MedImmune LLC, H2 2016 88

Systemic Lupus Erythematosus – Pipeline by Merck KGaA, H2 2016 89

Systemic Lupus Erythematosus – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 90

Systemic Lupus Erythematosus – Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 91

Systemic Lupus Erythematosus – Pipeline by Mount Tam Biotechnologies Inc, H2 2016 92

Systemic Lupus Erythematosus – Pipeline by Neovacs SA, H2 2016 93

Systemic Lupus Erythematosus – Pipeline by Nippon Chemiphar Co., Ltd., H2 2016 94

Systemic Lupus Erythematosus – Pipeline by Nuevolution AB, H2 2016 95

Systemic Lupus Erythematosus – Pipeline by Omeros Corporation, H2 2016 96

Systemic Lupus Erythematosus – Pipeline by Parvus Therapeutics, Inc., H2 2016 97

Systemic Lupus Erythematosus – Pipeline by Pfizer Inc., H2 2016 98

Systemic Lupus Erythematosus – Pipeline by Principia Biopharma Inc., H2 2016 99

Systemic Lupus Erythematosus – Pipeline by Ra Pharmaceuticals, Inc., H2 2016 100

Systemic Lupus Erythematosus – Pipeline by RedHill Biopharma Ltd., H2 2016 101

Systemic Lupus Erythematosus – Pipeline by Redx Pharma Plc, H2 2016 102

Systemic Lupus Erythematosus – Pipeline by Resolve Therapeutics, LLC, H2 2016 103

Systemic Lupus Erythematosus – Pipeline by Sanofi, H2 2016 104

Systemic Lupus Erythematosus – Pipeline by Sarepta Therapeutics, Inc., H2 2016 105

Systemic Lupus Erythematosus – Pipeline by SBI Biotech Co., Ltd., H2 2016 106

Systemic Lupus Erythematosus – Pipeline by Seattle Genetics, Inc., H2 2016 107

Systemic Lupus Erythematosus – Pipeline by Shire Plc, H2 2016 108

Systemic Lupus Erythematosus – Pipeline by Stemline Therapeutics, Inc., H2 2016 109

Systemic Lupus Erythematosus – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 110

Systemic Lupus Erythematosus – Pipeline by TheraMAB LLC, H2 2016 111

Systemic Lupus Erythematosus – Pipeline by Therapix Biosciences Ltd., H2 2016 112

Systemic Lupus Erythematosus – Pipeline by Thunderbolt Pharma Inc, H2 2016 113

Systemic Lupus Erythematosus – Pipeline by TxCell SA, H2 2016 114

Systemic Lupus Erythematosus – Pipeline by UCB SA, H2 2016 115

Systemic Lupus Erythematosus – Pipeline by Xencor, Inc., H2 2016 116

Systemic Lupus Erythematosus – Pipeline by XTL Biopharmaceuticals Ltd, H2 2016 117

Assessment by Monotherapy Products, H2 2016 118

Assessment by Combination Products, H2 2016 119

Number of Products by Stage and Target, H2 2016 121

Number of Products by Stage and Mechanism of Action, H2 2016 126

Number of Products by Stage and Route of Administration, H2 2016 131

Number of Products by Stage and Molecule Type, H2 2016 133

Systemic Lupus Erythematosus – Dormant Projects, H2 2016 394

Systemic Lupus Erythematosus – Dormant Projects (Contd..1), H2 2016 395

Systemic Lupus Erythematosus – Dormant Projects (Contd..2), H2 2016 396

Systemic Lupus Erythematosus – Dormant Projects (Contd..3), H2 2016 397

Systemic Lupus Erythematosus – Dormant Projects (Contd..4), H2 2016 398

Systemic Lupus Erythematosus – Dormant Projects (Contd..5), H2 2016 399

Systemic Lupus Erythematosus – Dormant Projects (Contd..6), H2 2016 400

Systemic Lupus Erythematosus – Dormant Projects (Contd..7), H2 2016 401

Systemic Lupus Erythematosus – Dormant Projects (Contd..8), H2 2016 402

Systemic Lupus Erythematosus – Discontinued Products, H2 2016 403

Systemic Lupus Erythematosus – Discontinued Products (Contd..1), H2 2016 404

List of Figures

List of Figures

Number of Products under Development for Systemic Lupus Erythematosus, H2 2016 22

Number of Products under Development for Systemic Lupus Erythematosus – Comparative Analysis, H2 2016 23

Number of Products under Development by Companies, H2 2016 24

Number of Products under Investigation by Universities/Institutes, H2 2016 29

Comparative Analysis by Late Stage Development, H2 2016 30

Comparative Analysis by Clinical Stage Development, H2 2016 31

Comparative Analysis by Early Stage Products, H2 2016 32

Assessment by Monotherapy Products, H2 2016 118

Number of Products by Top 10 Targets, H2 2016 120

Number of Products by Stage and Top 10 Targets, H2 2016 120

Number of Products by Top 10 Mechanism of Actions, H2 2016 125

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 125

Number of Products by Routes of Administration, H2 2016 130

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 130

Number of Products by Top 10 Molecule Types, H2 2016 132

Number of Products by Stage and Top 10 Molecule Types, H2 2016 132

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports